AzTrials
AzTrials

Geographic AtrophyPhase 2CATALINANCT04465955

A Study of NGM621 in Participants With Geographic Atrophy

A Phase 2 study testing NGM621 in people with Geographic Atrophy, run by NGM Biopharmaceuticals, Inc at 65 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration. Read more about this study

Who is it for?
Ages 55 years and older
Conditions the study is for
Geographic Atrophy
What is being tested?
NGM621
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
320 participants
Where
65 sitesUnited States
Study dates
22 Jul 2020to 16 Aug 2022
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female (non-pregnant, non-lactating) subjects ≥ 55 years
  • Standard luminance BCVA score of 34 letters or better using ETDRS charts at the starting distance of 4 meters (approximately 20/200 Snellen equivalent or better) in study eye
  • Clinical diagnosis of GA secondary to AMD:
  • Total GA area must be ≥ 2.5 and ≤ 17.5 mm²
  • If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm² (0.5 DA), with the overall area of GA ≥ 2.5 and ≤ 17.5 mm²
  • Well demarcated GA with no anatomical evidence of current or prior CNV in the study eye

Who cannot join

  • Study Eye
  • GA secondary to a condition other than AMD in either eye (e.g., monogenetic macular dystrophies like Stargardt disease, cone rod dystrophy, or toxic maculopathies)
  • Any history of or active choroidal neovascularization (CNV)
  • Both Eyes
  • Any history of or active bacterial, viral, fungal, or parasitic infection in either eye in the 3 months prior to randomization

Trial locations and contacts

65 sites in 1 country.

65 sites in 1 country

United States65 sites
  • Texas Retina Associates

    Arlington, Texas, 76012

  • Western Carolina Retinal Associates

    Asheville, North Carolina, 18803

  • California Retina Consultants

    Bakersfield, California, 93309

  • Thompson Sjaarda, PA

    Baltimore, Maryland, 21204

  • Elman Retina Group PA

    Baltimore, Maryland, 21237

  • Retina Vitreous Associates

    Beverly Hills, California, 90211

  • Gailey Eye Clinic - Bloomington

    Bloomington, Illinois, 61704

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114

  • Florida Eye Microsurgical Institute

    Boynton Beach, Florida, 33426

  • Retinal Diagnostic Center

    Campbell, California, 95008

  • Southeast Clinical Research

    Charlotte, North Carolina, 28210

  • University of Virginia

    Charlottesville, Virginia, 22903

  • University of Illinois

    Chicago, Illinois, 60612

  • Sterling Research Group, Ltd.

    Cincinnati, Ohio, 45219

  • Retina Associates of Cleveland

    Cleveland, Ohio, 44122

  • The Cleveland Clinic

    Cleveland, Ohio, 44195

  • Retina Consultants of Southern Colorado PC

    Colorado Springs, Colorado, 80909

  • University of Miami

    Coral Gables, Florida, 33146

  • Specialty Retina Center (Coral Springs)

    Coral Springs, Florida, 33067

  • Retina Foundation of the Southwest

    Dallas, Texas, 75231

  • Texas Retina Associates-Plano

    Dallas, Texas, 75231

  • Duke University

    Durham, North Carolina, 27705

  • The Retina Partners

    Encino, California, 91436

  • Retina Group of Florida

    Fort Lauderdale, Florida, 33308

  • National Ophthalmic Research Institute

    Fort Myers, Florida, 33912

  • Retina Consultants of Orange County

    Fullerton, California, 92835

  • Colorado Retina Associates PC

    Golden, Colorado, 80401

  • Long Island Vitreoretinal Consultants

    Great Neck, New York, 11021

  • Retina Consultants of Houston

    Houston, Texas, 77030

  • Raj K. Maturi, MD, PC

    Indianapolis, Indiana, 46290

  • Eye Care Specialists

    Kingston, Pennsylvania, 18704

  • Southeastern Retina Associates

    Knoxville, Tennessee, 37922

  • University Retina and Macula Associates, PC

    Lemont, Illinois, 60439

  • Loma Linda University Health

    Loma Linda, California, 92354

  • University of California Los Angeles

    Los Angeles, California, 90095

  • Georgia Retina PC

    Marietta, Georgia, 30060

  • Florida Eye Associates

    Melbourne, Florida, 32901

  • Vitreoretinal Surgery PA

    Minneapolis, Minnesota, 55435

  • Northern California Retina Vitreous Associates

    Mountain View, California, 94040

  • Tennessee Retina

    Nashville, Tennessee, 37203

  • Vitreous Retina Macula Consultants of NY

    New York, New York, 10022

  • Retina Institute of California

    Palm Desert, California, 92260

  • California Eye Specialists

    Pasadena, California, 91107

  • Retina Specialty Institute

    Pensacola, Florida, 32503

  • Retinovitreous Associates

    Philadelphia, Pennsylvania, 19107

  • Associated Retina Consultants

    Phoenix, Arizona, 85020

  • Retina Consultants San Diego

    Poway, California, 92064

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota, 57701

  • Sierra Eye Associates

    Reno, Nevada, 89502

  • Associated Retina Consultants PC

    Royal Oak, Michigan, 48073

  • Retinal Consultants Medical Group Inc

    Sacramento, California, 95841

  • University of California San Francisco

    San Francisco, California, 94143

  • Orange County Retina Medical Group

    Santa Ana, California, 92705

  • California Retina Consultants

    Santa Barbara, California, 93103

  • Retina Associates, PA

    Shawnee Mission, Kansas, 66204

  • Deep Blue Retina Clinical Research

    Southaven, Mississippi, 38671

  • Spokane Eye Clinical Research

    Spokane, Washington, 99204

  • Cascade Medical Research Institute

    Springfield, Oregon, 97477

  • Southern Vitreoretinal Associates

    Tallahassee, Florida, 32308

  • Retina Vitreous Associates of Florida

    Tampa, Florida, 33607

  • Retina Consultants of Houston

    The Woodlands, Texas, 77384

  • Associated Retina Consultants PC

    Traverse City, Michigan, 49686

  • Albany Troy Cataract & Laser Associates

    Troy, New York, 12180

  • New England Retina Associates PC

    Waterford, Connecticut, 06385

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas, 76087

Other trials in United States

About this study

Official title: A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

Being tested
NGM621, Sham Comparator
Medical subject headings
Geographic Atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NGM621Biological

    NGM621 Dose 1

  • NGM621Biological

    NGM621 Dose 2

  • Sham ComparatorOther

    Sham Comparator

Study groups in NCT04465955
Study groupRoleWhat they receive
NGM621 Treatment Group A (every 4 weeks)ExperimentalNGM621 single intravitreal (IVT) injection
Receives: Biological: NGM621
NGM621 Treatment Group C (every 8 weeks)ExperimentalNGM621 single IVT injection
Receives: Biological: NGM621
Sham Group B (every 4 weeks)Sham comparatorSham single IVT injection
Receives: Other: Sham Comparator
Sham Group D (every 8 weeks)Sham comparatorSham single IVT injection
Receives: Other: Sham Comparator

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area

    The rate of change from baseline in GA lesion area was measured by a non-invasive imaging technique called fundus autofluorescence (FAF) over the 52 weeks of treatment. FAF refers to the spontaneous emission of light by certain substances within the eye when exposed to a specific wavelength of light and involves quantifying the area and progression of atrophic lesions. The minimal GA lesion area is zero, the maximal GA lesion area is unknown. The higher the GA lesion area, the worse the visual outcome.

    Measured: Baseline to Week 52

  2. Number of Participants With Ocular Treatment-emergent Adverse Events in the Study Eye

    A treatment-emergent adverse event (TEAE) was an adverse event (AE) that occurred during or after the first dose of study treatment.

    Measured: Baseline to end of study (Week 56)

Secondary outcomes (12)
  1. The Change From Baseline in Geographic Atrophy (GA) Lesion Area

    Geographic atrophy lesion area was measured by a non-invasive imaging technique called fundus autofluorescence (FAF). FAF refers to the spontaneous emission of light by certain substances within the eye when exposed to a specific wavelength of light and involves quantifying the area and progression of atrophic lesions. The minimal GA lesion area is zero, the maximal GA lesion area is unknown. The higher the GA lesion area, the worse the visual outcome.

    Measured: Baseline up to Week 52

  2. The Rate of Change From Baseline in the Square Root of Geographic Atropy (GA) Lesion Area

    Geographic atrophy lesion area was measured by fundus autofluorescence (FAF). FAF refers to the spontaneous emission of light by certain substances within the eye when exposed to a specific wavelength of light and involves quantifying the area and progression of atrophic lesions.

    Measured: Baseline up to Week 52

  3. The Change From Baseline in Best Corrected Visual Acuity Score

    Best Corrected Visual Acuity Score is the best possible vision an eye can achieve with corrective lenses, typically glasses or contact lenses. BCVA was assessed by the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. ETDRS letter score is calculated when >20 letters are read correctly at 4.0 meters; the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters plus 30. If <20 letters are read correctly at 4.0 meters, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters (number of letters recorded on line 1.0), plus the total number of letters in the first six lines read correctly at 1.0 meter. Therefore, the ETDRS letter score could result in a score of 0-100, where lower scores indicate better vision.

    The change from baseline in BCVA is being report with negative scores indicating an improvement in vision.

    Measured: Baseline up to Week 52

  4. The Change From Baseline in Low Luminance Visual Acuity Score

    Low Luminance Visual Acuity Score measures vision in low-light conditions. It was assessed by the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters.

    ETDRS letter score is calculated when >20 letters are read correctly at 4.0 meters; the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters plus 30. If <20 letters are read correctly at 4.0 meters, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters (number of letters recorded on line 1.0), plus the total number of letters in the first six lines read correctly at 1.0 meter. Therefore, the ETDRS letter score could result in a score of 0-100, where lower scores indicate better vision.

    A lower (negative) LLVA score compared to baseline indicates a decline in visual acuity. A higher (positive) LLVA score compared to baseline indicates an improvement in visual acuity.

    Measured: Baseline up to Week 52

  5. The Change From Baseline in Low Luminance Deficit Score

    Low Luminance Deficit (LLD) Score was assessed by the Early Treatment of Diabetic Retinopathy Study (ETDRS) letters at a starting distance of 4 meters. ETDRS letter score is calculated when >20 letters are read correctly at 4.0 meters; the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters plus 30. If <20 letters are read correctly at 4.0 meters, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 meters (number of letters recorded on line 1.0), plus the total number of letters in the first six lines read correctly at 1.0 meter. Therefore, the ETDRS letter score could result in a score of 0-100, where lower scores indicate better vision.

    A LLD is the difference between standard visual acuity and LLVA, with a LLD >13 ETDRS letters suggesting potential visual abnormality. The change from baseline in LLD is being report with negative scores indicating an improvement in vision.

    Measured: Baseline up to Week 52

  6. The Change From Baseline in Average Binocular Reading Speed

    Average binocular reading speed was assessed by Minnesota Low-Vision Reading Test (MNRead) or Radner reading charts. The change from baseline in average binocular reading speed is reported with a higher (positive) reading speed (wpm) indicates better reading ability, while a lower (negative) reading speed indicates poorer reading ability.

    Measured: Baseline up to Week 52

  7. The Change From Baseline in Binocular Critical Print Size

    Binocular critical print size was assessed by the Minnesota Low-Vision Reading Test (MNRead) or Radner reading charts. MNRead uses a logarithmic scale (LogMAR) to represent print sizes, with each step representing a 0.1 LogMAR difference. The chart ranges from +1.3 LogMAR (equivalent to 20/400 at 40 cm) to -0.5 LogMAR (equivalent to 20/6 at 40 cm). The change from baseline in binocular critical print size is being reported with a higher (positive) LogMAR value for critical print size indicating that a person needs larger print sizes to maintain their maximum reading speed, while a lower (negative) LogMAR value indicates that they can read smaller print sizes at their maximum speed.

    Measured: Baseline up to Week 52

  8. The Change From Baseline in Binocular Reading Acuity

    Binocular reading acuity was assessed by the Minnesota Low-Vision Reading Test (MNRead) or Radner reading charts. MNRead uses a logarithmic scale (LogMAR) to represent print sizes, with each step representing a 0.1 LogMAR difference. The chart ranges from +1.3 LogMAR (equivalent to 20/400 at 40 cm) to -0.5 LogMAR (equivalent to 20/6 at 40 cm). Binocular reading acuity is the smallest print size (in LogMAR) that a person can read easily and accurately. The change from baseline in binocular reading acuity is being reported with a higher LogMAR value for reading acuity indicates poorer reading ability, while a lower LogMAR value indicates better reading ability.

    Measured: Baseline up to Week 52

  9. The Change From Baseline in Functional Reading Independence Index Composite Score

    The Functional Reading Independence (FRI) Index Composite Score is a 7-item patient questionnaire developed to evaluate the effect of geography atrophy on a patient's ability to independently perform reading activities. The FRI Index yields mean scores ranging from 1-4, with 1=unable to do and 4=totally independent. The FRI Index composite score is calculated by averaging the item-level scores across the seven questions, higher sores indicate better FRI. The change from baseline in FRI is being reported with lower (negative) values indicating a decline in FRI.

    Measured: Baseline up to Week 52

  10. The Change From Baseline in National Eye Institute Visual Functioning Questionnaire Composite Score

    The National Eye Institute Visual Functioning Questionnaire Composite Score is calculated by averaging the scores of the 11 vision-targeted subscales, excluding the general health rating question, on a scale of 0 to 100, with higher scores indicating better vision-related function. The change from baseline is being reported with a negative value indicating a decline in vision function.

    Measured: Baseline up to Week 52

  11. The Change From Baseline in Systemic Complement Activity (CH50)

    Systemic Complement Activity is a blood test that measures the overall activity of the complement system, a group of proteins crucial for the immune system's function. Low CH50 levels can be associated with certain infections. CH50 levels of 41 to 90 hemolytic units per mL (U/mL) is considered normal. The change from baseline in CH50 is being reported.

    Measured: Baseline up to Week 52

  12. Number of Anti-Drug Antibody (ADA)-Negative Participants

    The incidence of anti-drug antibody (ADA) was assessed in serum.

    Measured: Baseline up to Week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2020
  2. Study start22 Jul 2020
  3. Primary completion16 Aug 2022
  4. Study completion16 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
320 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04465955
Sponsor's protocol ID
621-GA-201
Acronym
CATALINA
Status last verified
Jun 2025
First submitted
1 Jul 2020
Last updated
1 Jul 2025
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Since the study did not meet the study endpoints, there is no plan to make IPD available to other researchers.

Publications

  • Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3.

    PubMed 37314061

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing NGM621 in people with Geographic Atrophy, run by NGM Biopharmaceuticals, Inc at 65 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 65 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Jul 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area (time frame: Baseline to Week 52). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04465955, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in